A ground-breaking blood test can accurately detect almost two thirds of deadly cancer cases, research has found. The Galleri test — dubbed the 'holy grail' for cancer — screens for more than 50 ...

Grail is on a mission to have its cancer blood test become a core part of U.S. screening for a range of tumors. Now, it’s detailing its latest data as it heads to the FDA. Back in June, Grail revealed ...

Hundreds of people who used Grail’s Galleri multicancer blood test reportedly received letters last month incorrectly indicating that they might have cancer. The Galleri liquid biopsy is designed to ...

MENLO PARK, Calif., Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been ...

CANTON, Mass. & MENLO PARK, Calif.--(BUSINESS WIRE)-- Point32Health, the parent company of Harvard Pilgrim Health Care, and GRAIL, LLC, a health care company with a mission of detecting cancer early ...

Nearly four years after first pitching for Grail Inc. (NASDAQ:GRAL), Illumina Inc. (NASDAQ:ILMN) announced Monday that it would spin off the cancer blood test developer. In July 2021, Illumina said it ...

San Diego gene-sequencing giant Illumina said Monday that its board approved the spinoff of early cancer-detecting startup Grail. The move brings the local biotechnology company one step closer to ...

Grail, which makes a blood test for cancer, said a vendor’s software issue caused inaccurate letters to be sent to about 400 customers last month. By Amanda Holpuch A company that developed a blood ...

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings from the PATHFINDER study of ...